- Home
- XERS vs SDGR Comparison
XERS vs SDGR Comparison
Compare XERS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | SDGR |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XERS | SDGR |
|---|---|---|
| Price | $7.32 | $17.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $10.43 | ★ $26.25 |
| AVG Volume (30 Days) | ★ 2.0M | 846.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $266,137,000.00 | $256,951,000.00 |
| Revenue This Year | $44.37 | $23.69 |
| Revenue Next Year | $27.87 | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.05 | 32.90 |
| 52 Week Low | $3.14 | $15.99 |
| 52 Week High | $10.08 | $28.47 |
Technical Indicators
Market Signals| Indicator | XERS | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 47.32 |
| Support Level | $6.95 | $17.02 |
| Resistance Level | $7.26 | $19.04 |
| Average True Range (ATR) | 0.32 | 0.78 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 86.67 | 33.00 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.